About E3 ubiquitin-protein ligase TRIM34
E3 ubiquitin-protein ligase TRIM34 (TRIM34) is a protein
from Homo sapiens identified by UniProt accession
Q9BYJ4, 488 residues long.
MolForge cross-references it against 0 known binders and
29 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIM34 |
| UniProt accession | Q9BYJ4 |
| Gene | TRIM34 |
| Organism | Homo sapiens |
| Length | 488 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (29)
Diseases linked to this target (Open Targets).
- PHF-tau measurement · score 0.17
- Familial prostate cancer · score 0.11
- prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- apolipoprotein B measurement · score 0.09
- infection · score 0.07
- infect · score 0.07
- low density lipoprotein cholesterol measurement · score 0.03
- non-small cell lung carcinoma · score 0.03
- platelet count · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BYJ4-F1 | alphafold | PREDICTED | 86.42 | — |
Amino-acid sequence (488 residues)
MASKILLNVQ EEVTCPICLE LLTEPLSLDC GHSLCRACIT VSNKEAVTSM GGKSSCPVCG ISYSFEHLQA NQHLANIVER LKEVKLSPDN GKKRDLCDHH GEKLLLFCKE DRKVICWLCE RSQEHRGHHT VLTEEVFKEC QEKLQAVLKR LKKEEEEAEK LEADIREEKT SWKYQVQTER QRIQTEFDQL RSILNNEEQR ELQRLEEEEK KTLDKFAEAE DELVQQKQLV RELISDVECR SQWSTMELLQ DMSGIMKWSE IWRLKKPKMV SKKLKTVFHA PDLSRMLQMF RELTAVRCYW VDVTLNSVNL NLNLVLSEDQ RQVISVPIWP FQCYNYGVLG SQYFSSGKHY WEVDVSKKTA WILGVYCRTY SRHMKYVVRR CANRQNLYTK YRPLFGYWVI GLQNKCKYGV FEESLSSDPE VLTLSMAVPP CRVGVFLDYE AGIVSFFNVT SHGSLIYKFS KCCFSQPVYP YFNPWNCPAP MTLCPPSS
Explore E3 ubiquitin-protein ligase TRIM34 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets